Effective of verapamil combination with vacuum for treatment of peyronie's disease

Effectiveness of verapamil compare with verapamil and vacuum in the treatment of Peyronie's disease

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200316046786N1

Enrollment

Registered

2020-06-21

Start date

2020-02-17

Completion date

Unknown

Last updated

2020-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peyronie disease. Disorder of penis, unspecified

Interventions

Intervention 1: Control group: patient have peyronie's disease and have routine treatment of verapamil 10mg each week for 6 weeks. Intervention 2: Intervention group: patient have peyronire's disease

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: All patient have peyronie's disease at least 6 months All patient have 90 c curvature in penis.

Exclusion criteria

Exclusion criteria: Patient have plaque in all part of penis patient have ventral curvature. patient have erection dysfunction with peyronie disease that have not respond to oral agent or ICI.

Design outcomes

Primary

Measure	Time frame
Diffrence in curvature of penis picture before and after trial. Timepoint: before trial and 6 week after trial. Method of measurement: patient take photo from his penis curvature.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyed mokhtar hossini

Ahvaz University of Medical Sciences

hamedkarimiafshar@gmail.com+98 61 3374 3033

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026